Igor Y. Khandros - Aug 31, 2021 Form 4 Insider Report for Berkeley Lights, Inc. (CELL)

Signature
/s/ Stuart L. Merkadeau, Attorney-in-fact for Igor Khandros
Stock symbol
CELL
Transactions as of
Aug 31, 2021
Transactions value $
-$2,673,649
Form type
4
Date filed
9/2/2021, 08:52 PM
Previous filing
Aug 26, 2021
Next filing
Sep 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CELL Common Stock Sale -$1.22M -34.6K -0.38% $35.13 9.1M Aug 31, 2021 See footnote F1, F2, F7
transaction CELL Common Stock Sale -$106K -2.9K -0.03% $36.69 9.1M Aug 31, 2021 See Footnote F1, F3, F7
transaction CELL Common Stock Sale -$808K -22.7K -0.25% $35.57 9.08M Sep 2, 2021 See Footnote F1, F4, F7
transaction CELL Common Stock Sale -$436K -11.9K -0.13% $36.70 9.06M Sep 2, 2021 See Footnote F1, F5, F7
transaction CELL Common Stock Sale -$108K -2.9K -0.03% $37.17 9.06M Sep 2, 2021 See Footnote F1, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, which will sell up to 2,000,000 shares amounting to less than 25% of Dr. Khandros total beneficially owned shares, in regular sales of 37,500 shares.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.85. The reporting person undertakes to provide Berkeley Lights, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.19 to $37.03. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.06 to $36.05. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.06 to $37.05. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.08 to $37.31. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 Consists of (i) 8,858,384 shares held by the Khandros-Bloch Revocable Trust U/A/D 1/24/1997 ("Revocable Trust"), (ii) 1,400 restricted stock units held by the Revocable Trust, (iii) 100,757 shares held by the Khandros 2018 3-Year GRAT (the "Khandros GRAT"), and (iv) 100,757 shares held by the Bloch 2018 3-Year GRAT (the "Bloch GRAT," and together with the Khandros GRAT, the "GRATs"). As co-trustee of the Revocable Trust and the GRATs, Dr. Khandros may be deemed to beneficially own the shares held by the Revocable Trust and the GRATs. Dr. Khandros disclaims beneficial ownership of the shares held by the Revocable Trust and the GRATs except to the extent of his pecuniary interest therein.